pancreatic NET
Oncology · 2011–2012
4decisions
2medicines
0carried consumer input
0individual submissions
Every decision here pre-dates the consumer comments facility, so no input would be recorded either way.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| sunitinib initial and continuing treatment of metastatic, unresectable, well-differentiated malignant pancreatic neuroendocrine tumour (or carcinoma) (pancreatic NET) in… | Jul 2012 | Recommended | unclear |
| sunitinib malate initial and continuing treatment of metastatic, unresectable, well-differentiated malignant pancreatic neuroendocrine tumour (or carcinoma) (pancreatic NET) in… | Mar 2012 | Deferred | no section in document |
| sunitinib malate Initial and continuing treatment of metastatic, unresectable, well-differentiated malignant pancreatic neuroendocrine tumour (pancreatic NET) in patients who… | Mar 2012 | Deferred | no section in document |
| sunitinib malate initial and continuing treatment of unresectable, well-differentiated pancreatic neuroendocrine tumour (pancreatic NET) in patients who are unsuitable for… | Jul 2011 | Not recommended | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 0 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.